Sunday, October 24, 2021
HomeLatest NewsCovid-19FDA Authorizes Additional mRNA COVID-19 Vaccines for Moderately to Severely Immunocompromised People

FDA Authorizes Additional mRNA COVID-19 Vaccines for Moderately to Severely Immunocompromised People

The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUA) for additional doses of both the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine for moderately to severely immunocompromised people. People with immunocompromising conditions or who take immunosuppressive medications or therapies are at increased risk for severe COVID-19. Studies indicate that some immunocompromised people have a reduced immune response following a primary COVID-19 vaccine series compared to vaccine recipients who are not immunocompromised. Studies have further demonstrated that an additional mRNA COVID-19 vaccine dose after an initial 2-dose primary mRNA COVID-19 vaccine series in some immunocompromised populations may enhance immune response.
It is also recommended that immunocompromised individuals discuss monoclonal antibody treatment options with their health care provider should they contract or be exposed to COVID-19. The FDA has authorized monoclonal antibody treatments for emergency use during this public health emergency for adults and pediatric patients (ages 12 and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. One authorized product includes use for preventative (prophylaxis) treatment after being exposed to SARS-CoV-2; however, this product is not a substitute for vaccination.
More information from the FDA is available here.

Stay Connected

Unified Voice Newsletter

Events This Month

october

26oct10:00 am12:00 pmSDAHO District III Fall Meeting10:00 am - 12:00 pm CST Event Type :District Meeting

26oct11:00 am12:00 pmEnd of Life series: Loss, Grief & Bereavement (Part 2)Webinar11:00 am - 12:00 pm CST Event Type :Education Events,Webinar

27oct1:00 pm2:30 pmCouncil Meeting: Clinical and Quality Integration1:00 pm - 2:30 pm CST Event Type :Board & Council Meeting

X


By submitting this form, you are consenting to receive marketing emails from: SDAHO, 3708 W Brooks Place, Sioux Falls, SD, 57106, http://sdaho.org. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact